We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
11 April 2018
The high cost of therapeutic protein production, whether for human or animal health, has limited the application and use of such cutting-edge therapeutics in developing countries. Alternative process technologies to traditional mammalian and bacterial expression systems have been explored by various groups and have led to clinical trials for several plant-expressed therapeutic proteins. The first plant-produced biological was marketed by Protalix and Pfizer for the treatment of Gaucher's disease and several global corporations are now involved in plant-based therapeutic protein production.
There are various advantages to the use of biopharming expression systems, including:
The South African government has focused on biopharming as a means of developing the bioeconomy for more than a decade. Biopharming was one of the 'grand challenges' of the Department of Science and Technology's 10-Year Innovation Plan. Accordingly, a number of South African research institutions and small and medium-sized enterprises (SMEs) are actively involved in plant-based expression platforms for various therapeutic proteins, leveraging the advantages of these systems for the development of therapeutic proteins for the treatment of neglected diseases, emerging diseases and highly communicable diseases that traditional therapeutic biological systems have either ignored or been too slow or expensive to roll out to the market, particularly in the developing world.
The two largest research groups focusing on the production of human and animal vaccines and therapeutic proteins using plants are situated at the Council for Scientific and Industrial Research (CSIR) and the University of Cape Town (UCT). For example, the CSIR has produced RabiVir – a plant-made antibody cocktail for rabies prophylaxis – and plant-made subunit animal vaccines. The UCT has shown the first proof of efficacy of a plant-produced papillomavirus vaccine for humans and is also involved in various plant-made subunit animal vaccines. Further, AzarGen Biotechnologies is a South African SME involved in therapeutic protein production in plants, with their leading candidate recombinant product being a human surfactant protein that increases the survivability of premature infants. AzarGen has partnered with iBio, a US commercial bio-manufacturer for plant-expressed protein production. However, if the South African biopharming industry continues with the momentum that it currently has, local biopharming manufacturing facilities are also likely to be established.
Biopharming regulation requires proper foundations in the form of biopharming rules and research and development policies. In South Africa, different government departments have already implemented legislation concerning plant-based protein production, including:
Given this infrastructure and the highly active local biopharming research community, South Africa is considered a promising jurisdiction for the production of plant-based therapeutic proteins, with many possible opportunities for investment and collaboration.
For further information on this topic please contact Joanne van Harmelen at ENSafrica by telephone (+27 21 410 2500) or email (email@example.com). The ENSafrica website can be accessed at www.ensafrica.com.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.